Screening for Gaucher and ASMD
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study screens people with an enlarged spleen and low platelet count for two rare genetic conditions: Gaucher disease and acid sphingomyelinase deficiency (ASMD). It aims to find people who might have these treatable disorders.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an enlarged spleen (splenomegaly).
- You have low platelet count (thrombocytopenia).
- You have not been diagnosed with Gaucher disease, ASMD, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for two rare inherited disorders—Gaucher disease and acid sphingomyelinase deficiency (ASMD)—in people who already have a blood condition like monoclonal gammopathy (abnormal protein) or multiple myeloma. If you have an enlarged spleen or low platelets, you may be eligible to help researchers understand if these rare diseases are more common in this group.
This study looks for tiny particles in blood (called extracellular vesicles) that may help identify Gaucher disease and could guide future treatments. It also studies people who have Gaucher gene carrier status but do not have the disease, using careful genetic testing.
This study looks at how standard treatments for Gaucher disease affect lung problems, bone damage, and parkinson-like symptoms. It aims to find better ways to treat these complications and improve quality of life.
This study is designed to learn what happens over time in people who have Gaucher disease. It may help researchers understand the long-term effects of the condition and improve future care.
This study looks at how Gaucher disease affects patients’ daily life and health outcomes through a survey. Your answers could help improve future care and treatments by showing what outcomes matter most.
This study tests an oral medication (eliglustat) for children with Gaucher disease types 1 and 3, replacing enzyme infusions. It may help maintain disease control with a simpler treatment.
Hear when a new Gaucher Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.